MAPT and Alzheimer disease: In addition, together with the existing suite of radioligands (e.g., amyloid and tau PET ligands), [18F]PF-06684511 could be explored in the evaluation of patients with AD, i.e., quantification of BACE1 expression in the brain and its correlation with disease progression.